Efficacy of intralesional recombinant human epidermal growth factor in chronic diabetic foot ulcers.

Abstract

OBJECTIVE:

The aim of this study was to explore the clinical effects of intralesional administration of an epidermal growth factor (EGF) up to complete wound closure.

METHODS:

Seventeen diabetic patients with full-thickness lower extremity ulcers of more than 4 weeks of evolution were enrolled in the study. Mean ulcer size was 15.5 +/- 7.5 cm(2). Intralesional injections of 75 µg of Heberprot-P three times per week for 5-8 weeks were given up to complete wound healing.

RESULTS:

Full granulation response was achieved in all patients in 32.4 +/- 6.6 days. Complete wound closure was obtained in 16 (94.1%) cases in 53.1 +/- 4.7 days. The most frequent adverse events were burning sensation, tremors, chills and pain at the site of administration. After 1-year follow-up, only one patient relapsed.

CONCLUSIONS:

Intralesional EGF administration up to complete closure can be safe, effective and suitable to improve healing of chronic diabetic foot ulcer (DFU).

• Authors: Mert Dumantepe, Osman Fazliogullari, Mustafa Seren, Ibrahim Uyar, Fahrettin Basar
• Journal: Growth factors (Chur, Switzerland) (Growth Factors) Vol. 33 Issue 2 Pg. 128-32 (Apr 2015) ISSN: 1029-2292 [Electronic] England
• PMID: 25856197 (Publication Type: Clinical Study, Journal Article)

Chemical References

• Recombinant Proteins
• Epidermal Growth Factor

Topics

• Aged
• Diabetic Foot (drug therapy)
• Epidermal Growth Factor (administration & dosage, therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Injections, Intralesional
• Male
• Middle Aged
• Recombinant Proteins (administration & dosage, therapeutic use)
• Risk Factors
• Time Factors
• Treatment Outcome
• Wound Healing